title: Effects of ultrasound contrast agents on Doppler tissue velocity estimation.
abstract: The combination of Doppler tissue imaging and myocardial contrast echocardiography has the potential to provide information about motion and perfusion of the myocardium in a single examination. The purpose of this study was to establish how the presence of ultrasound contrast agent (UCA) affects measurements of Doppler tissue velocities in vivo and in vitro. We performed echocardiography in 12 patients with ischemic heart disease before and immediately after a slow intravenous infusion of the UCA Optison, using color Doppler tissue imaging to examine the effect of contrast agents in vivo. The myocardial peak systolic velocities and their integrals were analyzed in digitally stored cineloops before and after contrast administration. To distinguish between methodologic and physiologic factors affecting the measurement of tissue velocity in vitro, experiments with a rotating disk and a flow cone phantom were also carried out for the 3 contrast agents: Optison, Sonovue, and Sonazoid. In vivo results show that the values for peak systolic velocity increased by about 10% during contrast infusion, from mean 5.2 +/- 1.8 to 5.7 +/- 2.3 cm/s (P = .02, 95% confidence interval 2%-16%). The increase in myocardial peak systolic velocities was verified in experimental models in which the UCA increased the estimated mean velocity in the order of 5% to 20% for the motion interval of 5 to 7 cm/s, corresponding to the myocardial velocities studied in vivo. The response was similar for all 3 contrast agents and was not affected by moderate variations in concentration of the agent. We have shown that the presence UCA will affect Doppler tissue measurements in vivo and in vitro. The observed bias is presumed to be an effect of harmonic signal contribution from rupturing contrast agent microbubbles and does not indicate biologic or physiologic effects.
authors.affiliation: Department of Biomedical Engineering, Linköping University, Linköping, Sweden. marcus.ressner@imt.liu.se
authors.forename: Marcus
authors.initials: M
authors.lastname: Ressner
authors.forename: Lars-Ake
authors.initials: LA
authors.lastname: Brodin
authors.forename: Tomas
authors.initials: T
authors.lastname: Jansson
authors.forename: Lars
authors.initials: L
authors.lastname: Hoff
authors.forename: Per
authors.initials: P
authors.lastname: Ask
authors.forename: Birgitta
authors.initials: B
authors.lastname: Janerot-Sjoberg
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000418:Albumins; D003287:Contrast Media; D004452:Echocardiography / Q000379:methods*; D005260:Female; D005290:Ferric Compounds; D005466:Fluorocarbons; D006801:Humans; D007089:Image Enhancement / Q000379:methods; D007090:Image Interpretation, Computer-Assisted / Q000379:methods; D007501:Iron; D008297:Male; D008875:Middle Aged; D009068:Movement; D009203:Myocardial Infarction; D017202:Myocardial Ischemia / Q000150:complications / Q000000981:diagnostic imaging*; D010087:Oxides; D010743:Phospholipids; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013318:Stroke Volume; D013459:Sulfur Hexafluoride; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000209:etiology
chemical_list: D000418:Albumins; D003287:Contrast Media; C099458:FS 069; D005290:Ferric Compounds; D005466:Fluorocarbons; D010087:Oxides; D010743:Phospholipids; C069727:Sonazoid; C420843:contrast agent BR1; D007501:Iron; D013459:Sulfur Hexafluoride